Literature DB >> 12840870

P53 gene mutations in non-Hodgkin's lymphoma.

Y Chen1, Z Xiang, H Li, N Yang, H Zhang.   

Abstract

To understand P53 gene change of non-Hodgkin's lymphoma (NHL) and human malignant lymphoma cell lines, the exons 5-7 of 29 patients with NHL and 9 kinds of human malignant lymphoma cell lines were studied by silver staining PCR-SSCP technique. Three cases of P53 gene point mutation was found in 29 cases of NHL. Mutation developed in exon 5 in 2 cases, and in exon 6 in 1 case. They were all diffuse lymphoma. In mutation cases, B-cell lymphoma accounted for 2 cases and the other one was T-cell lymphoma. There was no P53 gene mutation in low-grade follicular lymphoma. Seven strains out of 9 kinds of lymphoma cell lines had P53 gene point mutation. One strain had the mutation in exon 5; 5 strains in exon 6 and 1 strain in exons 5, 6, 7. There was a high mutation rate in lymphoma cell lines and low mutation rate in NHL patients. P53 gene plays an important role in lymphoma cell line establishment, cell regeneration and disease evolution.

Entities:  

Mesh:

Year:  1999        PMID: 12840870     DOI: 10.1007/bf02895589

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  3 in total

1.  Mutations of p53 gene and their relation to disease progression in B-cell lymphoma.

Authors:  A Ichikawa; T Hotta; N Takagi; K Tsushita; T Kinoshita; H Nagai; Y Murakami; K Hayashi; H Saito
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

2.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

Review 3.  The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies.

Authors:  C Preudhomme; P Fenaux
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.